Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: a long-term safety and feasibility study

Christian Elabd\textsuperscript{1}, Christopher J. Centeno\textsuperscript{2}, John R. Schultz\textsuperscript{2}, Gregory Lutz\textsuperscript{3}, Thomas Ichim\textsuperscript{4} and Francisco J. Silva\textsuperscript{1}\textsuperscript{*}

Abstract

Background: Chronic low back pain due to disc degeneration represents a major social and economic burden worldwide. The current standard of care is limited to symptomatic relief and no current approved therapy promotes disc regeneration. Bone marrow-derived mesenchymal stem cells (MSCs) are easily accessible and well characterized. These MSCs are multipotent and exhibit great tissue regenerative potential including bone, cartilage, and fibrous tissue regeneration. The use of this cell-based biologic for treating protruding disc herniation and/or intervertebral disc degeneration is a promising therapeutic strategy, due to their known regenerative, immuno-modulatory and anti-inflammatory properties.

Methods: Five patients diagnosed with degenerative disc disease received an intra-discal injection of autologous, hypoxic cultured, bone marrow-derived mesenchymal stem cells (15.1–51.6 million cells) as part of a previous study. These patients were re-consented to participate in this study in order to assess long-term safety and feasibility of intra-discal injection of autologous, hypoxic cultured, bone marrow-derived mesenchymal stem cells 4–6 years post mesenchymal stem cell infusion. The follow-up study consisted of a physical examination, a low back MRI, and a quality of life questionnaire.

Results: Patients' lower back MRI showed absence of neoplasms or abnormalities surrounding the treated region. Based on the physical examination and the quality of life questionnaire, no adverse events were reported due to the procedure or to the stem cell treatment 4–6 years post autologous, hypoxic cultured mesenchymal stem cell infusion. All patients self-reported overall improvement, as well as improvement in strength, post stem cell treatment, and four out of five patients reported improvement in mobility.

Conclusion: This early human clinical data suggests the safety and feasibility of the clinical use of hypoxic cultured bone marrow-derived mesenchymal stem cells for the treatment of lower back pain due to degenerative disc disorders and support further studies utilizing hypoxic cultured bone marrow-derived stem cells. The overall improvements reported are encouraging, but a larger double-blind, controlled, randomized clinical study with significant number of patients and implementation of validated endpoint measurements are next steps in order to demonstrate efficacy of this cell-based biologic.

*Correspondence: fsilva@biorestorative.com
\textsuperscript{1} BioRestorative Therapies, Inc., 40 Marcus Drive, Suite One, Melville, NY 11747, USA
Full list of author information is available at the end of the article
Background
Chronic low back pain affects approximately 632 million people worldwide and has an enormous social impact on patients and a significant economic impact on healthcare budgets [1]. In the United States alone, the annual cost is estimated to be as high as 500 billion dollars [2, 3]. The exact causes of disc degeneration are complex and involve genetic risks, smoking, obesity, aging and mechanical trauma [4]. The intervertebral disc is an immune-privileged avascular organ composed of fibrocartilaginous tissues that connect the vertebral bodies and provide stability, while allowing motion between the vertebrae [5, 6]. The centrally located nucleus pulposus is a hypoxic, hydrophilic proteoglycan-rich gelatinous core, surrounded by a lamellated collagenous ring, the annulus fibrosus and bony end-plates that separate the discs from the vertebrae [4, 7]. In a normal disc, there is a balance between the anabolic and catabolic capacity of the disc cells, but excessive stress can alter this balance and compromise extracellular matrix degradation and synthesis thereby initiating a degenerative cascade [8]. A loss in the cellular component function induces alterations in both the cartilaginous and proteoglycan matrix of the disc [4, 9, 10]. Subsequently, alterations of the proteoglycan component ultimately leads to dehydration of the nucleus pulposus, which impacts the ability of the disc to effectively distribute and recover from mechanical loading. The degenerated disc may eventually weaken to develop a protrusion towards the spine that puts pressure on the nerve roots or parts of the spinal canal, causing back pain and possibly weakness and numbness.

The standard of care for treating disc degeneration involves conservative non-surgical approaches or surgical interventions that target symptomatic relief and musculoskeletal stabilization. Currently, there is no clinical therapy targeting the reversal of disc degeneration or that addresses intervertebral disc cell homeostasis [11, 12]. The regenerative medicine field using cell-based therapies and biologics has advanced significantly over the past decade with numerous clinical trials aiming at providing treatments for neurodegenerative, orthopedic and cardiovascular disorders [11, 13–15]. Mesenchymal stem cells (MSCs) are stem cells that have extensive proliferative capacity and multi-lineage potential. They arise from progenitor cell reservoirs and have been isolated from various tissues, including bone marrow [16], muscle [17], and adipose tissue [18, 19]. MSCs isolated from various tissues share common characteristics, including the ability to: (1) form fibroblastic like colonies; (2) proliferate extensively; (3) be directionally differentiated into adipocytes, osteoblasts and chondrocytes; and (4) express several common cell surface markers. In addition, they possess immunomodulatory properties [20, 21] and have the ability to secrete a variety of cell mediators that aid in cellular repair and homeostasis.

The ideal treatment for degenerative disc disease (DDD) would be to conserve the physiologic function of intervertebral discs and reverse the degenerative cascade. The potential for stem cell-based therapy to treat disc degeneration is to repopulate the disc with viable cells capable of producing extracellular matrix, restoring damaged tissue and enhance tissue regeneration by the secretion of growth factors to modulate the inflammatory response. In this short report, we studied the long-term safety and feasibility (n = 5) of intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells for the treatment of chronic lumbar radiculopathy.

Rational for hypoxic cell therapy
The intervertebral disc is the largest avascular tissue in the human body, with oxygen gradients ranging between 1 and 5 % [22]. Nutrients such as glucose and oxygen diffuse from the capillaries across the cartilaginous end-plate and through the dense disc matrix to the cells. During disc degeneration, structural changes and vascular depletion reduce oxygen diffusion thus oxygen concentration lowers, resulting in further extracellular matrix degradation, ultimately causing a vicious cycle of disc degeneration. Several studies suggested that hypoxic pre-conditioning has beneficial biological effects that can impact the therapeutic activity of MSCs in the disc. Hypoxic culture has been demonstrated to upregulate chondrocyte specific genes such as aggrecan, collagen type II and Sox-9 [23], upregulate the expression of hypoxia inducible factor-1α (HIF-1α), increasing the anti-apoptotic capabilities of MSCs [24–26] and activating focal adhesion kinase (FAK), which increases migration and homing [27]. In addition, MSCs cultured from older patients under hypoxia demonstrated enhanced self-renewal and proliferation capacity compared to cultures under normoxic conditions [28]. Hypoxic culturing of MSCs produces many desirable biological effects that may impact the therapeutic activity of the MSCs post-transplant into the limited nutrient, low oxygen tension microenvironment of the degenerative disc.

Keywords: Regenerative medicine, Cell therapy, Degenerative disc disease, Autologous, Hypoxic, Mesenchymal stem cells, Bone marrow, Intra-discal injection, Safety, Feasibility
Methods
Study overview
The five patients described in this study where diagnosed with lumbar degenerative disc disease associated with protruding discs. Thirty-eight subjects were screened, seven patients were enrolled in the study and 5 patients completed the study. These patients, in procedures performed in the United States, received autologous, hypoxic cultured, bone marrow-derived mesenchymal stem cells under IRB protocol (IRB protocol# 00002637) between 2009 and 2010. All of these patients had failed lower back pain standard of care and pain management including oral medication, physical therapy, fluoroscopically-guided epidural steroid injections, and activity modification. Four to six years post-cell transplant (Table 1), these patients were re-consented to participate in this study under IRB protocol (IRB protocol #1140608) in order to evaluate long-term safety and feasibility of intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells. This study included a follow-up examination consisting of a physical examination, the completion of a quality of life questionnaire, and a spine MRI performed and interpreted by an independent radiology group (Table 2).

Patients’ inclusion and exclusion criteria
The five patients met ALL of the following criteria prior to receiving the injection of hypoxic-cultured MSCs:

1. Voluntary signature of the IRB approved informed consent.
2. Skeletally mature male or females between the ages of 18 and 65.
3. Pain, spasm, or functional disability in the low back and diagnosed as having painful DDD and having failed conservative treatments (e.g. NSAIDs, physician initiated physical therapy) for at least 3 months, but no longer than 5 years.
4. Significant functional disability related to pain, weakness, restricted range-of-motion or other back symptoms.
5. Either a painful annular fissure that is c/w physical exam and low pressure positive discography (painful P2 concordant response at less than 20 mmHG over opening pressure) or with or without Modic endplate changes.
6. If lumbar radiculopathy is present, it is due to a chemical radiculitis secondary to an annular fissure or small protrusion.
7. Is independent, ambulatory, and can comply with all post-operative evaluation and visits.

Candidates will be excluded if they meet ANY of the following criteria:

1. Symptomatic severe central canal or foraminal stenosis.
2. Previous history of lumbar spine surgery.
3. Prior epidural steroid injection within 12 weeks of the intra-discal procedure.
4. Lumbar radiculopathy caused by mechanical compression.
5. Spondylolisthesis/spondyloysis.
6. Inflammatory or auto-immune based pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, and gout pseudogout).
7. Quinolone or statin induced myopathy/tendinopathy.
8. Severe neurogenic inflammation of the cutaneous nerves.
9. Condition that represents a workers compensation case or pending litigation.
10. Pregnancy
11. Bleeding disorders

Table 1 Summary of treated patients

| Patient | Route       | Disc injected | Total MSCs injected (millions) | Follow up (years) | Adverse events |
|---------|-------------|---------------|--------------------------------|-------------------|---------------|
| 1       | Intra-discal| L5–S1         | 27.7                           | 5                 | None          |
| 2       | Intra-discal| L5–S1         | 51.6                           | 6                 | None          |
| 3       | Intra-discal| L5–S1         | 23.7                           | 4                 | None          |
| 4       | Intra-discal| L5–S1         | 15.1                           | 5                 | None          |
| 5       | Intra-discal| L4–L5         | 35.9                           | 5                 | None          |

Table 2 Safety parameters

| Patient | Physical exam | MRI | QoL* |
|---------|---------------|-----|------|
| 1       | X             | X   | X    |
| 2       | X             | X   | X    |
| 3       | X             | X   | X    |
| 4       | X             | X   | X    |
| 5       | X             | X   | X    |

* QoL: quality of life questionnaire
12. Currently taking anticoagulant or immunosuppressive medication.
13. Allergy or intolerance to study medication.
14. Use of chronic opioids.
15. Documented history of substance abuse within 6 months of treatment.
16. Any other condition, which in the opinion of the investigator, would preclude the patient from enrollment.

Isolation and hypoxic culture of autologous, bone marrow-derived mesenchymal stem cells
Bone marrow was harvested from each patient, as previously described [29]. Briefly, patients were placed in the prone position and 30 mL of bone marrow was harvested from each side of the posterior superior iliac spine area. The bone marrow aspirate was then centrifuged at 200×g for 6 min. The mononuclear cell layer was isolated and washed by centrifugation using phosphate buffered saline (PBS). Nucleated cells were plated into tissue culture flasks at a density of 1 × 10^6 cells/cm^2 and cultured in Dulbecco’s modified eagle medium (DMEM) with 10 % platelet lysate, 5 μg/mL doxycycline, and 2 IU/mL heparin in a 37 °C/5 % CO_2/5 % O_2 incubator. Mesenchymal stem cells were expanded under hypoxic conditions and prepared for injection.

Injection of hypoxic cultured autologous, bone marrow derived mesenchymal stem cells
On the day of injection, hypoxic expanded mesenchymal stem cells were harvested, washed and re-suspended in autologous platelet lysate at a final volume ranging between 0.25 and 1 mL. Under c-arm fluoroscopic guidance, a 22 gauge spinal needle was placed over the inferior articular process of the targeted spinal level to enter the annulus fibrosus of the intervertebral disc. The needle tip was then positioned on biplanar fluoroscopy in the middle of the nucleus pulposus (NP). A small amount of contrast was injected into the NP to demonstrate a nucleogram and filling of the annular fissure, followed by the intra-discal injection of the mesenchymal stem cells at the indicated cell quantity (Table 1).

Results
Below are individual case reports on the five patients included in the study. Summarized details of the patients and treatments are provided in Table 1. Overall safety evaluations performed are depicted in Table 2. Summarized data from the quality of life questionnaire are provided in Table 3. Patient MRIs pre- and post-intra-discal injection, are presented in Fig. 1 and a scatter plot showing overall improvement versus number of hypoxic cultured MSCs injected, is presented in Fig. 2.

Table 3 Summary of the quality of life questionnaire data

| Table 3 Summary of the quality of life questionnaire data |
|----------------------------------------------------------|
| Patient  | 1 | 2 | 3 | 4 | 5 |
|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Overall improvement (%) | 50 | 90 | 40 | 10 | 80–90 |
| Strength | Improved | Improved | Improved | Improved | Improved |
| Mobility | Improved | Improved | Improved | No change | Improved |

Patient 1
The patient is a 53-year-old female diagnosed with left thoracic outlet syndrome post trauma leading to chronic cervical and left arm pain. Patient also presented chronic lower back pain radiating into her leg on the left side extending down to the level of the knee. In March 2008, a pre-stem cell treatment baseline MRI of the lumbar region revealed that patient presented multilevel lumbar degenerative disc diseases at L4–L5 and L5–S1 with a posterior disc height of 10 mm and a posterior disc protrusion of 2 mm at the latter (Fig. 1a left). After being explained the experimental nature of the proposed procedure, informed consent was obtained. In November 2009, this patient received an intra-discal injection of 27.68 million autologous, hypoxic cultured bone marrow-derived MSCs. Cells were injected into the posterior annulus fibrosus of the L5–S1 intervertebral disc. No complications occurred during the procedure and no adverse events were reported directly following the procedure. In May 2014, the patient returned for a follow-up examination consisting of a physical examination, completion of a quality of life questionnaire, and a lower back MRI. The lower back MRI post MSC transplantation, showed no neoplasms or abnormalities surrounding the treated region (Fig. 1b right). MRI measurements showed a mild progression of the disc degeneration with a posterior disc height of 8 mm and a 25 % increase in the posterior protrusion from 2 to 2.5 mm (Fig. 1a right). As part of the quality of life questionnaire, the patient self-reported an overall improvement of 50 % post stem cell transplant as well as an increase in strength and range of motion (Table 3). No adverse events were reported due to the stem cell procedure based on the quality of life questionnaire and the physical examination.

Patient 2
The patient is a 25-year-old female with debilitating lower back pain with intermittent radiations down to her right leg. A pre-treatment MRI from July 2008 showed a significant reduction in disc height (8.5 mm), disc signal at L5–S1 with a posterior disc protrusion of 4.3 mm (Fig. 1b left). Patient was explained the experimental nature of the procedure and signed an informed consent.
Fig. 1 Patients MRI pre- and post- autologous, hypoxic cultured MSCs intra-discal injection. MRI pre- (left panels) and post- (right panels) stem cell treatment are shown for patient 1 (a), patient 2 (b), patient 3 (c), patient 4 (d), and patient 5 (e). Measurements of the posterior disc height and protrusion size at the L5–S1 level are indicated on each image as well as the date at which the MRI imaging was performed.
This patient received a total of 51.6 million autologous, hypoxic cultured bone marrow-derived MSCs divided in two injections per patient request. She was transplanted with 14.3 million MSCs on July 2008 and with 37.3 million MSCs on June 2009. Cells were delivered into the right posterior annulus fibrosus and at the annular/nuclear interface of the L5–S1 intervertebral disc. No complications occurred during the procedure and no adverse events were reported directly following the procedure. In April 2014 the patient returned for a follow-up examination consisting of a physical examination, completion of a quality of life questionnaire, and a lumbar MRI. The lumbar MRI post-MSC transplantation showed no neoplasms or abnormalities surrounding the treated region. MRI measurements showed a mild decrease in disc height (5.6 mm) and a 43% reduction of the posterior protrusion from 3.5 to 2.0 mm post stem cell treatment (Fig. 1c right). The patient self-reported an overall improvement of 40% post stem cell transplant as well as an increase in strength and range of motion (Table 3). No adverse events were reported due to the stem cell procedure based on the quality of life questionnaire and the physical examination.

Patient 3
The patient is a 40-year-old male with low back pain radiating into his right leg for 18 months prior to MSC injection. A baseline pre-stem cell treatment MRI imaging was performed on March 2010 and showed single L5–S1 level disc degeneration with a posterior disc height of 6.6 mm and a posterior disc protrusion of 3.5 mm (Fig. 1c left). After being explained the experimental nature of the proposed procedure, informed consent was obtained. On May 2010, this patient received an intra-discal injection of 23.7 million autologous, hypoxic cultured bone marrow-derived MSCs. Cells were injected into the L5–S1 intervertebral disc. No complications occurred during the procedure and no adverse events were reported directly following the procedure. The patient returned for a follow-up examination in July 2014 consisting of a physical examination, completion of a quality of life questionnaire, and a lumbar MRI. The lumbar MRI post-MSC transplantation showed no neoplasms or abnormalities surrounding the treated region. MRI measurements showed a mild progression of the posterior disc height loss (6.9 mm) and a 40% reduction of the posterior protrusion from 4.1 to 2.5 mm post stem cell treatment (Fig. 1d right). The patient self-reported in the quality of life questionnaire an overall improvement of 10% post stem cell transplant and an increase in strength while patient’s range of motion remained unchanged (Table 3). No adverse events were reported due to the stem cell procedure based on the quality of life questionnaire and the physical examination.
procedure based on the quality of life questionnaire and the physical examination.

Patient 5
The patient is a 41-year-old male with chronic lower back pain and bilateral radiculopathy more pronounced on the left side. In April 2009, a pretreatment MRI showed multilevel DDD from L3–L4 to L5–S1 levels, with disc protrusions at both L4–L5 and L5–S1 levels. At the L5–S1 level, the posterior disc height was measured at 5.8 mm and the protrusion at 6.5 mm (Fig. 1e left). After being explained the experimental nature of the proposed procedure, informed consent was obtained. In August 2009, this patient received an intra-discal injection of 35.9 million autologous, hypoxic cultured bone marrow-derived MSCs. Cells were injected into the posterior annulus fibrosus of the L5–S1 intervertebral disc. No complications occurred during the procedure and no adverse events were reported directly following the procedure. The patient returned for a follow-up examination in July 2014 consisting of a physical examination, completion of a quality of life questionnaire, and a lumbar MRI. The lumbar MRI post MSC transplantation showed no neoplasms or abnormalities surrounding the treated region. MRI measurement showed maintenance of the posterior disc height (5.8 mm) and a 48% reduction of the disc protrusion from 6.5 to 3.4 mm (Fig. 1e right). Based on the quality of life questionnaire, the patient self-reported an overall improvement of 80–90% post stem cell transplant in addition to an increase in strength and range of motion (Table 3). No adverse events were reported due to the stem cell procedure based on the quality of life questionnaire and the physical examination.

Discussion
There is a clear unmet medical need, prior to surgical intervention, for patients with chronic lower back pain associated with DDD. The standard of care including physiotherapy and corticosteroid epidural injections allows for pain management, at least initially, but does not frequently lead to prolonged pain relief and functional improvement. The degenerative cascade associated with DDD often leads over time to the aggravation of the symptoms at the affected disc level, but also to the deterioration of the adjacent intervertebral discs. After exhausting non-invasive options, patients face the prospect of surgery and, in particular, lumbar spinal fusion that does not guarantee complete pain alleviation and can present with significant complications and morbidity [30].

Regenerative medicine and stem cell therapies have gained tremendous interest in the past decades in multiple clinical applications and could represent a non-surgical biologic approach to improve pain and function in the millions of patients suffering from chronic low back pain associated with degenerative disc disease. Bone marrow-derived MSCs are of particular interest since they are easily accessible, they have been extensively studied, and they can be isolated following validated, standard operating procedures.

In the present study, we evaluated the safety and feasibility of an intra-discal injection of autologous, hypoxic cultured bone marrow-derived MSCs in five patients with chronic lower back pain. The five patients received between 15.1 and 51.6 million MSCs. These patients consented to a follow up exam 4–6 years post-MSC infusion consisting of a physical examination, completion of a quality of life questionnaire, and a lower back MRI. Data collected comprehensively showed that no adverse events, related to MSC infusion, occurred at the time of injection or up to 6 years post-injection, demonstrating long-term safety.

It is interesting to note that four out of five patients showed an improvement (reduction) of the protrusion size. Additionally all patients displayed maintenance or only mild worsening in disc height after long term follow up. Importantly, based on the quality of life questionnaires, the majority of patients reported an overall improvement, as well as an improvement in strength and mobility. Although this represents a small sample group, there appears to be a correlation between the total number of hypoxic cultured MSCs injected and the overall improvement reported by patients (Fig. 2).

Autologous, hypoxic cultured bone marrow-derived MSCs represent a potential attractive avenue for the regenerative treatment of patients with DDD. Preliminary safety data from the present study suggest that autologous, bone marrow-derived, hypoxic cultured MSCs are suitable for intra-discal injection of degenerated discs. Although these observations are encouraging, based on the small patient sample size and the uncontrolled nature of the study, a larger double-blind, controlled, randomized clinical study with significant number of patients and implementation of validated endpoint measurements such as the visual analog scale (VAS) pain scale and the functional rating index (FRI) test are next steps in order to demonstrate efficacy of this cell-based biologic.

Conclusions
Intra-discal injection of autologous, hypoxic cultured bone marrow-derived MSCs demonstrated safety and feasibility in five patients diagnosed with degenerative disc disease. This data further support the clinical use of such MSCs for the treatment of lower back pain in larger clinical studies.
Abbreviations
DD: degenerative disc disease; MSC(s): mesenchymal stem cell(s); MRI: magnetic resonance imaging; VAS: visual analog scale; FRI: functional rating index; Qol.: quality of life; NP: nucleus pulposus.

Authors’ contributions
CE analyzed and compiled the data and wrote the manuscript. CJC performed the study, collected the data and edited the manuscript. JRS performed the study and collected the data. GL and TI edited the manuscript. FJS supervised the study, analyzed and compiled the data and wrote the manuscript. All authors read and approved the final manuscript.

Author details
1 BioRestorative Therapies, Inc., 40 Marcus Drive, Suite One, Melville, NY 11747, USA. 2 The Centeno-Schultz Clinic, 403 Summit Boulevard, Unit 201, Broomfield, CO 80021-8253, USA. 3 Department of Physiatry, Hospital for Special Surgery, 429 E 75th Street, 3rd Floor, New York, NY 10021, USA. 4 Institute for Molecular Medicine, Huntington Beach, CA 92649, USA.

Acknowledgements
We thank Mark Weinreb and Edward Field for careful reading of the manuscript.

Competing interests
CE and FJS are shareholders and employed by BioRestorative Therapies, Inc. CJC and JRS are party to a license agreement with BioRestorative Therapies, Inc. GL is the Chief Medical Advisor for Spine Medicine, a shareholder, and a paid advisor to BioRestorative Therapies, Inc. TI declared no competing interests.

Availability of data and materials
Data and materials used can be obtained by contacting the corresponding author.

Consent for publication
Patients have consented for data to be used for research and publication purposes.

Ethics approval and consent to participate
All patients participating in the present study gave written informed consent as described in IRB protocol #00002637 and IRB protocol #1140608.

Trial registration number
Registry protocol was provided by a U.S. Office of Human Research Protections registered organization (IRB protocol #00002637)

Received: 29 June 2016 Accepted: 18 August 2016

Published online: 01 September 2016

References
1. Mathew J, Singh SB, Garis S, Diwan AD. Backing up the stories: the psychological and social costs of chronic low-back pain. Int J Spine Surg. 2013;7:e29–38.
2. Dagenais S, Tricco AC, Haldeman S. Synthesis of recommendations for the assessment and management of low back pain from recent clinical practice guidelines. Spine J. 2010;10:514–29.
3. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–96.
4. Urban JPG, Roberts S. Degeneration of the intervertebral disc. Arthritis Res Ther. 2003;5:120–30.
5. Roberts S, Evans H, Trivedi J, Menage J. Histology and pathology of the human intervertebral disc. J Bone Joint Surg Am. 2006;88(Suppl 2):10–4.
6. Meltroe J, Smith SM, Little CB, Moore RJ, Vennon-Roberts B, Fraser RD. Recent advances in annular pathology provide insights into rim-lesion mediated intervertebral disc degeneration and potential new approaches to annular repair strategies. Eur Spine J. 2008;17:1131–48.
7. Roughley PJ. Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. Spine. 2004;29:2691–9.
8. Antoniou J, Steffen T, Nelson F, Winterbottom N, Hollandier AP, Poole RA, et al. The human lumbar intervertebral disc: evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J Clin Invest. 1996;98:996–1003.
9. Gruber HE, Hanley EN. Observations on morphologic changes in the aging and degenerating human disc: secondary collagen alterations. BMC Musculoskelet Disord. 2002;3:9.
10. Gruber HE, Hanley EN. Analysis of aging and degeneration of the human intervertebral disc: Comparison of surgical specimens with normal controls. Spine. 1998;23:751–7.
11. Vasiliadis ES, Pneumatikos SG, Evangelopoulos DS, Papavassiliou AG. Biologic treatment of mild and moderate intervertebral disc degeneration. Mol Med. 2014;20:400–9.
12. Siepe CJ, Heider F, Wiechert K, Hitzt W, Ishak B, Mayer MH. Mid- to long-term results of total lumbar disc replacement: a prospective analysis with 5- to 10-year follow-up. Spine J. 2014;14:1417–31.
13. Canesi M, Giordano R, Lazzari I, Isalberti M, Isaia IU, Benti R, et al. Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. J Transl Med. 2016;14:127.
14. Centeno CJ, Al-Sayegh H, Freeman MD, Smith J, Munell WD, Rubakov R. A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions. Int Orthop. 2016;40(8):1755–65.
15. Patel AN, Mittal S, Turan G, Winters AA, Henry TD, Ince H, et al. REVIVE trial: retrograde delivery of autologous bone marrow in patients with heart failure. Stem Cells Transl Med. 2015;4:1021–7.
16. Li H, Ghazanfar R, Zacharakis D, Lim HC, Scheding S. Isolation and characterization of primary bone marrow mesenchymal stromal cells. Ann NY Acad Sci. 2016;1370:109–18.
17. Pavyde E, Maciulaitis R, Mauricas M, Sudzius G, Ivačauskaitė Didziobiene E, Laurinavičius A, et al. Skeletal muscle-derived stem/progenitor cells: a potential strategy for the treatment of acute kidney injury. Stem Cells Int. 2016;2016:9619480.
18. Rodriguez A-M, Elabd C, Amri E-Z, Aliauhaud G, Dani C. The human adipose tissue is a source of multipotent stem cells. Biochim. 2005;87:125–8.
19. Silva FJ, Holt DJ, Vargas V, Yockman J, Boudina S, Atkinson D, et al. Metabolically active human brown adipose tissue derived stem cells. Stem Cells. 2014;32:572–81.
20. Pourgholamnejad A, Aghdami N, Baharvand H, Moazzeni SM. The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells. Cytokine. 2016;85:51–60.
21. Chen W, Huang Y, Han J, Yu L, Li Y, Lu Z, et al. Immunomodulatory effects of mesenchymal stromal cell-derived exosomes. Immunol Res. 2016;64(4):831–40.
22. Risbud MV, Schipani E, Shapiro IM. Hypoxic regulation of mesenchymal stem cell survival: from niche to notch. Am J Pathol. 2010;176:1577–83.
23. Adesida AB, Mulet-Sierra A, Jomha NM. Hypoxia mediated isolation and expansion enhances the chondrogenic capacity of bone marrow mesenchymal stromal cells. Stem Cell Res Ther. 2012;3:9.
24. Zhang Y, Lee W, Yan W, Li X, Wang X, Zhao Z, et al. microRNA-206 is involved in survival of hypoxia preconditioned mesenchymal stem cells through targeting Pim-1 kinase. Stem Cell Res Ther. 2016;7:61.
25. Yu Y, Zhou Y, Cheng T, Lu X, Yu K, Zhou Y, et al. Hypoxia enhances tenocyte differentiation of adipose-derived mesenchymal stem cells by inducing hypoxygen-inducible factor-1α in a co-culture system. Cell Prolif. 2016;49:173–84.
26. Shah J, Liu H, Li J, Zhou Y, Roles of hypoxia during the chondrogenic differentiation of mesenchymal stem cells. Curr Stem Cell Res Ther. 2014;9:141–7.
27. Tsai C-C, Yew T-L, Yang D-C, Huang W-H, Hung S-C. Benefits of hypoxic culture on bone marrow multipotent stromal cells. Ann J Blood Res. 2012;2:148–59.
28. Mohsin N, Boo L, Yeap SK, Khyy S, Satharasinda DC, Liew WC, et al. Probable impact of age and hypoxia on proliferation and microRNA expression profile of bone marrow-derived human mesenchymal stem cells. Peer J. 2016;4:1536.
29. Centeno CJ, Schultz JR, Cheever M, Freeman M, Faulkner S, Robinson B, et al. Safety and complications reporting update on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther. 2011;6:368–78.

30. Baliga S, Treon K, Craig NJA. Low Back Pain: current surgical approaches. Asian Spine J. 2015;9:645–57.